Developing tender swelling or rash on their hands and feet may actually be good news for patients being treated with Xeloda® (capecitabine).
During a recent clinical trial, colorectal cancer patients with hand-foot syndrome lived longer, and it took longer for their cancer to get worse.
Researchers comparing two Xeloda-based chemotherapies for people with advanced colorectal cancer, studied skin side effects from both Xeloda and Erbitux® (cetuximab). They found that about a third of patients experienced at least some hand-foot syndrome, and these patients lived almost 10 months longer than patients without skin changes. Read the rest of this entry »